Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Lipid Metabolism Disorders

ClinicalTrials.gov lists 4,334 trials for Lipid Metabolism Disorders or a narrower condition beneath it. AstraZeneca has the most among industry and government lead sponsors, with 130.

MeSH D052439 Nutritional and Metabolic Diseases C18
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 478 Phase 1/2 Phase 1/2 109 Phase 2 Phase 2 446 Phase 2/3 Phase 2/3 67 Phase 3 Phase 3 667 Phase 4 Phase 4 415 Not applicable Not applicable 1,204 Observational Observational 925 Phase 1 Phase 1 478 Phase 1/2 Phase 1/2 109 Phase 2 Phase 2 446 Phase 2/3 Phase 2/3 67 Phase 3 Phase 3 667 Phase 4 Phase 4 415 Not applicable Not applicable 1,204 Observational Observational 925

Trials per phase

2 more sections with rows

176 of the 4,334 trials are tagged with Lipid Metabolism Disorders itself; the rest are tagged with a narrower condition beneath it.

Get the Lipid Metabolism Disorders report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Lipid Metabolism Disorders trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 9 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 216

1990: 4 trials (Observational 3, Phase 2 1) 1991: 7 trials (Observational 5, Phase 4 1, Phase 3 1) 1992: 7 trials (Observational 3, Phase 3 2, Phase 2 1, Phase 1 1) 1993: 5 trials (Observational 1, Phase 3 1, Phase 2 1, Phase 1 2) 1994: 4 trials (Observational 2, Phase 4 1, Phase 2 1) 1995: 6 trials (Observational 2, Not applicable 1, Phase 3 1, Phase 2/3 1, Phase 2 1) 1996: 5 trials (Observational 2, Not applicable 1, Phase 3 1, Phase 2 1) 1997: 5 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 1 1) 1998: 14 trials (Observational 3, Not applicable 2, Phase 3 1, Phase 2 6, Phase 1/2 1, Phase 1 1) 1999: 23 trials (Observational 5, Not applicable 3, Phase 4 2, Phase 3 3, Phase 2 3, Phase 1 7) 2000: 37 trials (Observational 10, Not applicable 3, Phase 4 4, Phase 3 11, Phase 2/3 1, Phase 2 7, Phase 1 1) 2001: 38 trials (Observational 11, Not applicable 3, Phase 4 7, Phase 3 10, Phase 2/3 1, Phase 2 4, Phase 1 2) 2002: 66 trials (Observational 7, Not applicable 10, Phase 4 10, Phase 3 17, Phase 2/3 3, Phase 2 12, Phase 1 7) 2003: 100 trials (Observational 14, Not applicable 6, Phase 4 26, Phase 3 34, Phase 2/3 1, Phase 2 14, Phase 1/2 1, Phase 1 4) 2004: 113 trials (Observational 19, Not applicable 17, Phase 4 21, Phase 3 30, Phase 2/3 1, Phase 2 14, Phase 1/2 3, Phase 1 8) 2005: 148 trials (Observational 17, Not applicable 22, Phase 4 37, Phase 3 46, Phase 2/3 1, Phase 2 18, Phase 1/2 3, Phase 1 4) 2006: 165 trials (Observational 22, Not applicable 33, Phase 4 23, Phase 3 45, Phase 2/3 5, Phase 2 27, Phase 1/2 2, Phase 1 8) 2007: 172 trials (Observational 30, Not applicable 37, Phase 4 19, Phase 3 40, Phase 2/3 5, Phase 2 23, Phase 1/2 2, Phase 1 16) 2008: 153 trials (Observational 23, Not applicable 35, Phase 4 23, Phase 3 31, Phase 2/3 1, Phase 2 26, Phase 1/2 5, Phase 1 9) 2009: 143 trials (Observational 33, Not applicable 30, Phase 4 26, Phase 3 17, Phase 2/3 4, Phase 2 10, Phase 1/2 9, Phase 1 14) 2010: 157 trials (Observational 50, Not applicable 35, Phase 4 21, Phase 3 12, Phase 2/3 4, Phase 2 13, Phase 1/2 4, Phase 1 18) 2011: 199 trials (Observational 30, Not applicable 43, Phase 4 20, Phase 3 33, Phase 2/3 4, Phase 2 31, Phase 1/2 2, Phase 1 36) 2012: 188 trials (Observational 26, Not applicable 62, Phase 4 17, Phase 3 22, Phase 2/3 8, Phase 2 18, Phase 1/2 5, Phase 1 30) 2013: 162 trials (Observational 24, Not applicable 52, Phase 4 9, Phase 3 32, Phase 2 19, Phase 1/2 4, Phase 1 22) 2014: 174 trials (Observational 44, Not applicable 47, Phase 4 10, Phase 3 20, Phase 2 14, Phase 1/2 6, Phase 1 33) 2015: 171 trials (Observational 35, Not applicable 51, Phase 4 11, Phase 3 23, Phase 2/3 5, Phase 2 16, Phase 1/2 3, Phase 1 27) 2016: 186 trials (Observational 42, Not applicable 59, Phase 4 16, Phase 3 26, Phase 2/3 5, Phase 2 15, Phase 1/2 2, Phase 1 21) 2017: 159 trials (Other 1, Observational 37, Not applicable 45, Phase 4 15, Phase 3 20, Phase 2/3 2, Phase 2 16, Phase 1/2 4, Phase 1 19) 2018: 173 trials (Observational 40, Not applicable 56, Phase 4 18, Phase 3 24, Phase 2/3 1, Phase 2 11, Phase 1/2 4, Phase 1 19) 2019: 173 trials (Observational 40, Not applicable 65, Phase 4 12, Phase 3 14, Phase 2/3 6, Phase 2 13, Phase 1/2 7, Phase 1 16) 2020: 160 trials (Observational 52, Not applicable 51, Phase 4 10, Phase 3 14, Phase 2 16, Phase 1/2 4, Phase 1 13) 2021: 184 trials (Observational 45, Not applicable 60, Phase 4 7, Phase 3 32, Phase 2 13, Phase 1/2 9, Phase 1 18) 2022: 189 trials (Observational 55, Not applicable 59, Phase 4 8, Phase 3 21, Phase 2 15, Phase 1/2 7, Phase 1 24) 2023: 203 trials (Observational 53, Not applicable 79, Phase 4 11, Phase 3 19, Phase 2/3 2, Phase 2 12, Phase 1/2 7, Phase 1 20) 2024: 216 trials (Observational 53, Not applicable 90, Phase 4 8, Phase 3 19, Phase 2/3 3, Phase 2 12, Phase 1/2 6, Phase 1 25) 2025: 169 trials (Observational 36, Not applicable 72, Phase 4 6, Phase 3 15, Phase 2/3 1, Phase 2 12, Phase 1/2 5, Phase 1 22)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 176
2025 169
2024 216
2023 203
2022 189
2021 184
2020 160
2019 173
2018 173
2017 159

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 200 trials starting in 2026 and about 190 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 268 trials still running at the 2026-10-09 snapshot; registered median of 17 months across 2,845 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Lipid Metabolism Disorders trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 478
Phase 1/2 109
Phase 2 446
Phase 2/3 67
Phase 3 667
Phase 4 415
Not applicable 1,204
Observational 925
Expanded access 22
Unknown 1

How many Lipid Metabolism Disorders trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 134
Recruiting 345
Enrolling by invitation 35
Active, not recruiting 138
Available 8

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Lipid Metabolism Disorders trials? (15)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
AstraZeneca 130
Organon and Co 100
Takeda 72
Sanofi 66
Merck Sharp & Dohme LLC 59

Showing 5 of 15 sponsors.

Start your 14-day trial Email me all 15 sponsors as a PDF

Which drugs are being tested for Lipid Metabolism Disorders? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
ATORVASTATIN 220
ROSUVASTATIN 144
Ezetimibe 125
SIMVASTATIN 88
Evolocumab 57

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle) 49
pitavastatin Ca 2mg 35
Pravastatin Pill 32
1% Metformin 32
Inclisiran (Leqvio®) 300mg 30

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Lipid Metabolism Disorders trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 2,040 127
Angina unstable 1,829 96
Angina pectoris 1,752 111
Osteoarthritis 1,388 79
Atrial fibrillation 1,144 100

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Lipid Metabolism Disorders? (10)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
HDL Cholesterol Efflux Capacity is Impaired in Severe Short-Term Hypothyroidism Despite Increased HDL Cholesterol. The Journal of clinical endocrinology and metabolism 2020 Yes
Pathogenesis of Lipid Disorders in Insulin Resistance: a Brief Review. Current diabetes reports 2018 Yes
The effect of maternal chromium status on lipid metabolism in female elderly mice offspring and involved molecular mechanism. Bioscience reports 2017 Yes
Monoacylglycerol-enriched oil increases EPA/DHA delivery to circulatory system in humans with induced lipid malabsorption conditions. Journal of lipid research 2016 Yes
Metabolic and mitochondrial myopathies. Neurologic clinics 2014 Yes

Showing 5 of 10 publications.

Start your 14-day trial Email me all 10 publications as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Disorder of lipid metabolism 309005 Exact Orphadata Science knowledge files, Product 1
Disorder of lipid metabolism 309005 Exact Orphanet Rare Disease Ontology (ORDO)

Sub-conditions in MeSH (5)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence.

Browse all condition evidence pages